Skip to main content
. 2013 Oct 25;2(5):e000136. doi: 10.1161/JAHA.113.000136

Table 6.

Target‐Specific Anticoagulants Approved for Use

Indication Dabigatran Rivaroxaban Apixaban
Stroke prevention in AF 150 mg twice daily 20 mg once daily 5 mg twice daily
Acute VTE treatment Not approved 20 mg once daily Not approved
VTE prevention in TKA or THA 220 mg once daily* 10 mg once daily 2.5 mg twice daily*

AF indicates atrial fibrillation; THA, total hip arthroplasty; TKA, total knee arthroplasty; VTE, venous thromboembolism.

*

Only approved in Europe and Canada for this indication.